Development of NOTCH1-selective small molecule inhibitor for the treatment of cancer
Ended Project Grant Awarded Last action
- Award ID
- R44CA261490
- Recipient
-
Stemsynergy Therapeutics Inc. UEI WVEMHJFUNJ97
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,898,781
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Funding
-
- $3,953,182.00 Federal
- $945,599.00 Non-federal
- Place of performance
- Tennessee, USA
Award details come from USAspending.gov.
Description
- Abstract
- The incidence of esophageal adenocarcinoma (EAC) has tripled over the last 40 years, but five-year overall survival is still poor due to late stage diagnosis, metastasis, and high rates of recurrence after standard chemotherapy. Standard-of-care therapy (neoadjuvant chemotherapy, radiation, or both followed by esophagectomy) achieves only 20% response rates, while 80% of patients remain poorly responsive. Recently, we have shown that aberrant activation of NOTCH1 signaling correlates with poor therapeutic responses and outcomes in EAC patients and that EAC tumors are dependent upon sustained NOTCH1 activity. The vast majority of r & d efforts to inhibit notch have focused on gamma secretase inhibitors (gsis), which inhibit all notch proteins, and as a result cause significant dose-limiting toxicity, largely hampering their clinical utility to date. Thus, there is a significant unmet clinical need for targeted therapies against NOTCH1-dependent cancers such as EAC. Stemsynergy therapeutics has identified a first-in-class inhibitor series that binds and inhibits the NOTCH1 transcriptional complex and limits transcription of downstream effectors of NOTCH1 signaling. We have demonstrated that only NOTCH1-dependent EAC cell lines are sensitive to our inhibitors, which blocked the growth of EAC patient-derived xenograft tumors. We further improved pharmacokinetics and specificity to produce our lead clinical candidate sstn-302, which is a highly potent and selective inhibitor of NOTCH1 and inhibits EAC tumor growth in vivo. Furthermore, sstn-302 has promising adme properties, high oral bioavailability, and most importantly - avoids the dose-limiting toxicity of gsis. This direct phase II proposal seeks to determine the preclinical safety of sstn-302 for the purposes of advancing a novel NOTCH1 inhibitor into the clinic.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $1,030,992 | $0 | |
| Amendment | $1,030,992 | $0 | |
| Amendment | $945,599 | $0 | |
| Original award | $945,599 | $945,599 |
Quick answers
Who received award R44CA261490?
R44CA261490 was awarded to Stemsynergy Therapeutics Inc. by National Cancer Institute (National Institutes of Health) on September 1, 2021.
How much is award R44CA261490 worth?
$4,898,781 has been obligated on R44CA261490: $3,953,182 in federal funding and $945,599 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award